Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Simon Wan Yau Ming"'
Publikováno v:
European Medical Journal (2022)
Introduction: First-line regular systemic treatment for atopic dermatitis (AD) in the UK consists of methotrexate, azathioprine, ciclosporin, or mycophenolate (immune-suppressive therapies [IST]). ISTs have been associated with malignancy, hence the
Externí odkaz:
https://doaj.org/article/99a4bfc52cd744dfa6b90e15e965217f
Autor:
David B. Price, Sinthia Bosnic-Anticevich, Ian D. Pavord, Nicolas Roche, David M. G. Halpin, Leif Bjermer, Omar S. Usmani, Guy Brusselle, Simon Wan Yau Ming, Sarang Rastogi
Publikováno v:
Clinical and Translational Allergy, Vol 9, Iss 1, Pp 1-18 (2019)
Abstract Background Blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO) concentration are established biomarkers in asthma, associated particularly with the risk of exacerbations. We evaluated the relationship of BEC and FeNO as c
Externí odkaz:
https://doaj.org/article/f6ba531f997e457cb351930ce40e72cb
Autor:
David B Price, Eran Gefen, Gokul Gopalan, Rosie McDonald, Vicky Thomas, Simon Wan Yau Ming, Emily Davis
Publikováno v:
PLoS ONE, Vol 13, Iss 1, p e0191404 (2018)
Ventolin Nebules® (reference product; GlaxoSmithKline) was the first licensed nebulizer solution containing the rapid-onset, short-acting β2-agonist salbutamol. Salbutamol Steri-Neb™ (comparator; Teva Pharmaceuticals, Inc.) has the same chemical
Externí odkaz:
https://doaj.org/article/8d72a144638d42cd80121b8a9e728e67
Autor:
Aikaterini Bilitou, John Were, Archie Farrer, Adrian Rabe, Simon Wan Yau Ming, Inaam Haq, Kyle Dunton
Publikováno v:
ClinicoEconomics and Outcomes Research. 14:189-203
Aikaterini Bilitou,1 John Were,2 Archie Farrer,2 Adrian Rabe,2,3 Simon Wan Yau Ming,2 Inaam Haq,1 Kyle Dunton4 1Daiichi Sankyo Europe GmbH, Munich, Bayern, Germany; 2Health iQ Ltd, London, UK; 3Imperial College London, London, UK; 4Daiichi Sankyo UK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::715e3473b1b6d9d7301249e65a0ec5f8
https://doi.org/10.2147/ceor.s347085
https://doi.org/10.2147/ceor.s347085
Autor:
Matthias Ochel, Shishir Patel, Iain Small, Federico Lavorini, Janwillem W. H. Kocks, Dermot Ryan, Alberto Papi, Simon Wan Yau Ming, Dave Singh, Victoria Carter, David M.G. Halpin, David Price, John Haughney, John R. Hurst, Antony Hardjojo
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease. 15:3093-3103
Introduction The Fostair® 100/6 (BDP/FF) pressurized metered-dose inhaler, delivering an extrafine formulation, is licensed for asthma and COPD in the UK. However, its real-life effectiveness for COPD has not been evaluated. This study compared the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f425a4d2b0a86246cb13eabaffc3998
https://doi.org/10.2147/copd.s263745
https://doi.org/10.2147/copd.s263745
Autor:
Karen Mezzi, Chin Kook Rhee, Janwillem W. H. Kocks, David Price, John R. Hurst, Konstantinos Kostikas, Simon Wan Yau Ming, Robert Fogel, Rupert Jones, Hui Cao, Ronan Ryan, Piergiuseppe Agostoni
Publikováno v:
Pragmatic and Observational Research. 11:55-66
Purpose Chronic obstructive pulmonary disease (COPD) and heart failure (HF) often occur concomitantly, presenting diagnostic and therapeutic challenges for clinicians. We examined the characteristics of patients prescribed adequate versus inadequate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17ffe9141636d8abd3e3c8a6181dd4e5
https://doi.org/10.2147/por.s250451
https://doi.org/10.2147/por.s250451
Autor:
Antony Hardjojo, David Price, Victoria Carter, Simon Wan Yau Ming, Job F M van Boven, Dukyong Yoon, Hyun Young Lee, Hae-Sim Park, Ga-Young Ban, Joanna Ling Zhi Jie
Publikováno v:
Respirology, 24(10), 972-979. Wiley
BACKGROUND AND OBJECTIVE: Mixed inhaler device use for asthma is associated with worse inhaler technique and outcomes. Given that relievers are commonly prescribed as pressurized metred-dose inhalers (pMDI), changing preventers from dry powder inhale
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f4a4925177c7c4c65b4f407699fdf3f
https://doi.org/10.1111/resp.13559
https://doi.org/10.1111/resp.13559
Autor:
Deog Kyeom Kim, Simon Wan Yau Ming, Joanna Zhi Jie Ling, Hae-Sim Park, Chin Kook Rhee, Job F M van Boven, Kwang Ha Yoo, Hye Yun Park, David Price
Publikováno v:
Journal of Allergy and Clinical Immunology: In Practice, 7(3), 934-942. American Academy of Allergy, Asthma and Immunology
BACKGROUND: Inhaler usability and deposition differ between devices. Change of device may therefore have an impact on clinical and economic outcomes.OBJECTIVE: To characterize clinical and economic asthma outcomes surrounding the change from a dry po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecf6f7f72c3cc8256874f2b269a294b8
https://hdl.handle.net/11370/2542ea6e-4f1a-4388-86d0-b1eeaaed157a
https://hdl.handle.net/11370/2542ea6e-4f1a-4388-86d0-b1eeaaed157a
Autor:
Stylianos Loukides, Antony Hardjojo, Sinthia Bosnic-Anticevich, Sen Yang, David Price, Victoria Carter, Simon Wan Yau Ming, Vicky Kritikos, Paul Dorinsky, Claudia Cabrera, Andriana I. Papaioannou
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
David B Price,1,2 Sen Yang,1 Simon Wan Yau Ming,1 Antony Hardjojo,1 Claudia Cabrera,3,4 Andriana I Papaioannou,5 Stelios Loukides,5 Vicky Kritikos,6 Sinthia Z Bosnic-Anticevich,6 Victoria Carter,7 Paul M Dorinsky8 1Observational and Pragmatic Researc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b15d4d1b7c0d2df5a720a9c5968088b
https://doi.org/10.2147/copd.s174371
https://doi.org/10.2147/copd.s174371
Autor:
John Haughney, Elizabeth Gardener, Cathal Daly, Simon Wan Yau Ming, Stephanie Wolfe, Martina Stagno d'Alcontres, David Price, Derek Skinner, Iain Small, Kevin Gruffydd-Jones, John Hamill, Joan B. Soriano
Publikováno v:
Respiratory Medicine. 129:199-206
Objective Asthma has a substantial impact on quality of life and health care resources. The identification of a more cost-effective, yet equally efficacious, treatment could positively influence the economic burden of this disease. Fluticasone propio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc5fa31301ccc6f183c8aafdc03769da
https://doi.org/10.1016/j.rmed.2017.06.016
https://doi.org/10.1016/j.rmed.2017.06.016